Sartorius AG · XETR:SRT

Sartorius — Investor Presentation (March 2016)

42 slides from Sartorius's investor presentation, March 2016

  1. Slide 1: Company Presentation

    Company Presentation March 2016 1

  2. Slide 2: Agenda

    Agenda 01 Sartorius in Brief 02 Bioprocess Solutions 03 Lab Products & Services 04 Sartorius 2020 05 Appendix 2

  3. Slide 3: Sartorius in 2015

    Sartorius in 2015 Internationally leading Bioprocess and Laboratory Technologies Provider ~34% ~45% ~21% > €1.1 bn. €113 mn. Americas EMEA Asia | Pacific Sales revenue Investments €263 mn. 23.6% Earnings1 EBITDA margin1 Sales revenue by region Listed since 1990; Part of German TecDax Figures as of D

  4. Slide 4: Global Player with around 50 Sales and Production Sites

    Global Player with around 50 Sales and Production Sites Asia|Pacific Americas India | Thailand | Singapore | Canada | USA: New Vietnam | China | Malaysia | York, Pennsylvania, South Korea | Japan | Australia Delaware, Colorado | Puerto Rico | Mexico | EMEA Peru | Brazil | Argen- Netherlands | Belgiu

  5. Slide 5: More than 6,200 Employees Worldwide

    More than 6,200 Employees Worldwide ~800 ~4,400 ~1,000 Americas EMEA Asia|Pacific 2,000 3,000 4,000 5,000 6,000 1996 1997 1998 1999 2001 2002 2003 2004 2005 2006 2008 2009 2010 2011 2013 2014 Discover Sartorius 1995 2000 2007 2012 2015 5

  6. Slide 6: Our Corporate Values

    Our Corporate Values a SUSTAINABILITY Growing profitably and taking responsibility for all stakeholders OPENNESS Driving change internally and externally ENJOYMENT Working in an energetic and rewarding environment #:- Sartorius

  7. Slide 7: Roots of Both Divisions Reach Far Back

    Roots of Both Divisions Reach Far Back 1870 1927 University mechanician | Company founder Florenz Wilhelm Sartorius founds joint venture with Nobel Sartorius invents short-beam analytical balance laureate and creator of membrane filtration Richard Zsigmondy Weighing Technology Filtration Core of Lab

  8. Slide 8: Business Development Spanning More than 140 Years

    Business Development Spanning More than 140 Years 1870 Florenz Sartorius founds Mid-90s Positioning as precision machine workshop biopharma supplier 2007 Biotechnology Division merges with 1927 Membrane filter Stedim to Sartorius Stedim Biotech company is founded 2011 New Division Lab Products & Reb

  9. Slide 9: Two Divisions

    Two Divisions 73% 27% of sales of sales revenue revenue Bioprocess Solutions Lab Products & Services Innovative single-use products and Premium lab instruments, consumables equipment for the manufacture of biologics and services for R&D, QA and QC Figures as of Dec. 31, 2015 9

  10. Slide 10: Agenda

    Agenda 01 Sartorius in Brief 02 Bioprocess Solutions 03 Lab Products & Services 04 Sartorius 2020 05 Appendix 10

  11. Slide 11: What Are Biopharmaceuticals?

    What Are Biopharmaceuticals? ~20.000 Atoms Living, genetically modified cells Production Injection | Infusion Advantages Challenges  First-time or improved treatment of serious illnesses,  R&D and production labor-intensive such as cancer, multiple sclerosis, rheumatism  High therapy costs: biolo

  12. Slide 12: Trend towards Manufacturing Single-use Technologies

    Trend towards Manufacturing Single-use Technologies Past Present High initial cost + CAPEX reduction over entire lifecycle Considerable cleaning effort + Lower water and energy consumption Risk of cross-contamination + Higher flexibility 12

  13. Slide 13: BPS Generates 75% of its Business with Single-use Products

    BPS Generates 75% of its Business with Single-use Products Equipment ~ 25 % Single-Use ~ €809mn. ~ 75 % Figures as of Dec. 31, 2015 13

  14. Slide 14: Total Solution Provider across the Biopharma Process Chain

    Total Solution Provider across the Biopharma Process Chain Process development Production Cell Culture Media Fermentation Cell Harvesting Buffer|Preparation Purification Services 14

  15. Slide 15: Leading Market Positions Worldwide

    Leading Market Positions Worldwide Filtration TOP 3 Fluid Management #1 Fermentation #1  > 85 % of sales revenue generated from TOP 1-3 positions 15

  16. Slide 16: Agenda

    Agenda 01 Sartorius in Brief 02 Bioprocess Solutions 03 Lab Products & Services 04 Sartorius 2020 05 Appendix 16

  17. Slide 17: Research Labs Need Intelligent Lab Instruments

    Research Labs Need Intelligent Lab Instruments  Assistance systems reduce user errors  Laboratory data are processed automatically  Ergonomic design minimizes physical strain 17

  18. Slide 18: Quality Assurance Labs Accompany every Step of Food and Pharma Production

    Quality Assurance Labs Accompany every Step of Food and Pharma Production  Sample collection  Quality assurance  Clearance  Documentation 18

  19. Slide 19: These Products and Services are Must-Haves in Any Laboratory

    These Products and Services are Must-Haves in Any Laboratory 40% of sales revenue 60% of sales revenue Lab Instruments Consumables Services  Balances  Syringe Filters  Installation  Pipettes  Microbiological Test Kits  Servicing | Repair  Lab Water Systems  Pipette Tips  Qualification (IQ/O

  20. Slide 20: Customers

    Expansion of Direct Sales including eBusiness Pharma | Biotech Lab Distributors Sales Channels Customers focus Academia Direct Sales expand Clin. Diagnostics | Chemicals eBusiness build up Food & Beverage 20

  21. Slide 21: Leading Market Positions Worldwide

    Leading Market Positions Worldwide Lab Balances #2 Pipettes #4 Consumables #3 Lab Water Systems #4  Average global market share > 10%  Significant growth potential, especially in USA and Asia 21

  22. Slide 22: Agenda

    Agenda 01 Sartorius in Brief 02 Bioprocess Solutions 03 Lab Products & Services 04 Sartorius 2020 05 Appendix 22

  23. Slide 23: Profitable Growth in Past 10 Years

    Profitable Growth in Past 10 Years 1,114.8 40 35 887.3 891.2 845.7 30 733.1 659.3 25 622.7 611.6 602.1 23.6 521.1 20 484.3 21.0 19.0 19.5 18.6 16.7 15 15.3 13.7 14.1 12.8 13.1 10 5 0 2 3 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Sales revenue € in mn. Underlying EBITDA margin1 1 Underly

  24. Slide 24: Ambitious Growth Targets Up to 2020

    Ambitious Growth Targets Up to 2020 Strategic Initiatives 2020 Targets Regional  North America: Gain market share  Asia | esp. China: Leverage strong market growth ~€ 2 bn.1 Sales Revenue Portfolio ~3/4 ~1/4  Expansion through alliances and acquisitions Organic Acquisitions  Own product developm

  25. Slide 25: Gain Market Share in North America; Leverage Strong Market Growth in Asia

    Regional Gain Market Share in North America; Leverage Strong Market Growth in Asia ~ 17% ~ 13% CAGR1 Americas Sales share2 CAGR1 Asia | Pacific Americas 34% ~€1.1 bn. 21% Asia | Pacific North America - the largest market Asia - the strongest-growing for biopharma and lab products pharma and lab mark

  26. Slide 26: Complementary Alliances & Acquisitions Add to Growth

    Portfolio Complementary Alliances & Acquisitions Add to Growth Umetrics ABER Cellca BD BlueSens BioOutsource Metroglas Lonza Cell Culture Media Südpack Medica Wave Biotech ATMI Life Sciences Biohit Liquid Handling NIR Online c-LEcta Toha Plast TAP Biosystems LevTech Omnimark Bosch Packaging ProMetic

  27. Slide 27: Further Expansion of Bioprocess Portfolio

    Portfolio Further Expansion of Bioprocess Portfolio Process development Production Small-scale single-use bioreactors Q4 2013 Cell culture media Q1 2013 Single-use technology Support of process for sampling development Q3 2015 Q2 2014 Testing in biosafety and bioanalytics Q2 2015 27

  28. Slide 28: Alliances Speed up Innovation

    Portfolio Alliances Speed up Innovation Single-use sensors for biomass measurement Sensors for oxygen and carbon dioxide measurement Ready-to-use, prefilled media products for microbiological applications Single-use sensors for flow rate measurement 28

  29. Slide 29: New Products

    Portfolio New Products Syringeless One-step Filters Innovative Operating Concepts Simple, multiplexing sample preparation Fast and reliable results New PE Film for Single-use Bags Single-use Clarification System Improved cell growth High flow rates, flexible scalability 29

  30. Slide 30: Strong R&D in Core Technologies

    Portfolio Strong R&D in Core Technologies Technologies  Membranes, non-wovens  Plastics processing: Injection molding, extrusion, welding|gluing  Sensors, automation & control  Bioanalytics & cell biology  Process analytics  Mechatronics Applications  Biotechnology and biopharma  Quality ass

  31. Slide 31: Investments into Infrastructure Foster Profitable Growth

    Infrastructure Investments into Infrastructure Foster Profitable Growth Capex ratio 9.1 10.1 ~ 10 8.8 Konzern 7.1 7.7 3.7 2010 2011 2012 2013 2014 2015 20161  Capacity expansion at international sites  Extension and harmonization of IT infrastructure 1 Estimated 31

  32. Slide 32: New Sartorius Campus to Further Boost Innovative Strength and Efficiency

    Infrastructure New Sartorius Campus to Further Boost Innovative Strength and Efficiency  Consolidation of the two major Goettingen sites into one site  ~€500 million investment program extending up to 2020  Further expansion of filter, membrane and lab instrument production capacity  Building to

  33. Slide 33: Agenda

    Agenda 01 Sartorius in Brief 02 Bioprocess Solutions 03 Lab Products & Services 04 Sartorius 2020 05 Appendix 33

  34. Slide 34: Expansion in Stages of Sartorius Campus

    Infrastructure Expansion in Stages of Sartorius Campus Membrane Membrane Marketing| Lab Instruments R&D production casting machine Cafeteria Manufacturing - 2016 - - under construction - Bioprocess Solutions Receiving Facility Main Entrance| Manufacturing College area Mgmt. Administration - under co

  35. Slide 35: Next Steps

    Infrastructure Next Steps Lab Instruments Manufacturing Main Entrance | Administration Marketing | Cafeteria 35

  36. Slide 36: Portfolio Bioprocess Solutions

    Portfolio Bioprocess Solutions Filtration Purification 36

  37. Slide 37: Portfolio Bioprocess Solutions

    Portfolio Bioprocess Solutions Fluid Management Fermentation & Cell Culture Media 37

  38. Slide 38: Portfolio Lab Products & Services

    Portfolio Lab Products & Services Lab Balances Pipettes 38

  39. Slide 39: Portfolio Lab Products & Services

    Portfolio Lab Products & Services Lab Water Systems Further Lab Instruments 39

  40. Slide 40: Portfolio Lab Products & Services

    Portfolio Lab Products & Services Lab Filtration Microbiological Quality Control 40

  41. Slide 41: Questions & Answers

    Questions & Answers 41

  42. Slide 42: Disclaimer

    Disclaimer This presentation contains statements concerning Sartorius Groups’ future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is b

Sartorius — Investor Presentation (March 2016) on 6ix